Detalhe da pesquisa
1.
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 390(23): 2143-2155, 2024 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38899693
2.
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Blood
; 139(4): 538-553, 2022 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-34624079
3.
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
Cell Rep Med
; 4(11): 101244, 2023 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37858338
4.
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Nat Commun
; 13(1): 5469, 2022 09 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36115844
5.
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Nat Commun
; 13(1): 5830, 2022 Oct 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36192480